Systemic delivery of blood–brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Delivery of therapeutic agents to the central nervous system is a significant challenge, hindering progress in the treatment of diseases such as glioblastoma. Due to the presence of the blood-brain barrier (BBB), therapeutic agents do not readily transverse the brain endothelium to enter the parenchyma. Previous reports suggest that surface modification of polymer nanoparticles (NPs) can improve their ability to cross the BBB, but it is unclear whether the observed enhancements in transport are large enough to enhance therapy. In this study, we synthesized two degradable polymer NP systems surface-modified with ligands previously suggested to improve BBB transport, and tested their ability to cross the BBB after intravenous injection in mice. All the NP preparations were able to cross the BBB, although generally in low amounts (<0.5% of the injected dose), which was consistent with prior reports. One NP produced significantly higher brain uptake (∼0.8% of the injected dose): a block copolymer of polylactic acid and hyperbranched polyglycerol, surface modified with adenosine (PLA-HPG-Ad). PLA-HPG-Ad NPs provided controlled release of camptothecin, killing U87 glioma cells in culture. When administered intravenously in mice with intracranial U87 tumors, they failed to increase survival. These results suggest that enhancing NP transport across the BBB does not necessarily yield proportional pharmacological effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×
“Moreover, although PEG has been shown to reduce immunogenicity of certain macromolecules [57], anti-PEG immune responses have been observed when PEGylated nanomedicines were repeatedly injected [58]; the production of anti-PEG IgM was associated with accelerated blood clearance.”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“In addition, Ad has been found to bind G-protein coupled receptors A1, A2A, A2B and A3 on different cells in the body [65].”
BackgroundFormulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Cited by
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
“prepared two degradable polymer NPs systems modified with ligands (rabies virus glycoprotein, TGN and adenosine) to investigate their penetration ability after being intravenously injected into mice [89].”
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
Zhang, W., Mehta, A., Tong, Z., Esser, L., & Voelcker, N. H. (2021) · Advanced Science · doi:10.1002/advs.202003937 · Cited by 430
Strategies for transporting nanoparticles across the blood–brain barrier
Zhang, T.-T., Li, W., Meng, G., Wang, P., & Liao, W. (2016) · Biomaterials Science · doi:10.1039/c5bm00383k · Cited by 308
Drug targeting strategies into the brain for treating neurological diseases
Barnabas, W. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.015 · Cited by 70
Metadata
- Authors
- Saucier-Sawyer, J. K., Deng, Y., Seo, Y.-E., Cheng, C. J., Zhang, J., Quijano, E., & Saltzman, W. M.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2015-09-14
- Volume
- 23
- Issue
- 7-8
- Pages
- 736-749
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2171802467
- Cited by
- 98
- References
- 15
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic delivery of blood–brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. https://app.cochat.ai/papers/10.3109/1061186x.2015.1065833
- The paper
- Saucier-Sawyer, J. K., Deng, Y., Seo, Y.-E., Cheng, C. J., Zhang, J., Quijano, E., & Saltzman, W. M. (2015). Systemic delivery of blood–brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. Journal of Drug Targeting. https://doi.org/10.3109/1061186x.2015.1065833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.